Video

ONC-CHAT: 'VOGL, NEW YORK' on 10 Years of Tamoxifen


 

"VOGL, NEW YORK" is how Dr. Steven Vogl identifies himself when he stands up at major oncology meetings. He is by now well known for his pointed questions, and received a plaque at the 2010 San Antonio Breast Cancer Symposium in recognition of his unique contribution. Here is his take on a major study presented in 2012.

Recommended Reading

San Antonio Roundtable, Part 1: Fulvestrant Dose and Tamoxifen Duration
MDedge Hematology and Oncology
Experimental Drug Puts ER-Positive Breast Cancer on Hold
MDedge Hematology and Oncology
Less Invasive Biopsy Used Less in Black Breast Cancer Patients
MDedge Hematology and Oncology
Doubling Fulvestrant Dose Extends Breast Cancer Survival
MDedge Hematology and Oncology
Ten Years of Adjuvant Tamoxifen Found Superior to Five
MDedge Hematology and Oncology
Bevacizumab Adds No Progression, Survival Benefits to Estrogen Therapy
MDedge Hematology and Oncology
Mammograms Dip in Wake of USPSTF Recommendations
MDedge Hematology and Oncology
San Antonio Roundtable, Part 2: CALOR Trial, Triple-Negative Breast Cancer
MDedge Hematology and Oncology
PET/CT Pinpoints Physiological Evidence of Chemo Brain
MDedge Hematology and Oncology
ONC-CHAT - What Did You Learn at the Meeting Today?
MDedge Hematology and Oncology